Bayesian clinical trial design using Markov models with applications to autoimmune disease

Barry S. Eggleston, Joseph G. Ibrahim, Diane Catellier

Research output: Contribution to journalArticle

Abstract

Immune Thrombocytopenia is an autoimmune disease associated with bleeding that is treated by increasing the platelet count to a level where the chance of uncontrollable bleeding is low. Failure occurs when platelet counts are not raised sufficiently (initial failure), or when high platelet counts are not maintained after initial success (relapse). In this paper, we propose a Bayesian clinical trial design that uses a Markov multistate model along with a power prior for the parameters which incorporates historical control data to estimate transition rates among two randomized groups as defined by the model. A detailed simulation is carried out to examine the operating characteristics of a trial to test whether a new treatment reduces the relapse rate by 40% relative to standard care when data from 60 historical controls treated with standard care is available. We also use simulated data to demonstrate effects of discordance between historical and randomized controls on the estimated hazard ratios. Finally, we use a simulated trial to demonstrate briefly what type of results the model can give and how those results can be used to address hypotheses regarding treatment effects. Using simulated data, we show that the model yields good operating characteristics when the historical and randomized controls are from the same population, and demonstrate how discordance between the control groups affects the operating characteristics.

LanguageEnglish (US)
Pages73-83
Number of pages11
JournalContemporary Clinical Trials
Volume63
DOIs
StatePublished - Dec 1 2017

Fingerprint

Platelet Count
Autoimmune Diseases
Clinical Trials
Hemorrhage
Recurrence
Idiopathic Thrombocytopenic Purpura
Control Groups
Population

Keywords

  • Bayesian methods
  • Clinical trial design
  • Illness-death model
  • Markov models

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Bayesian clinical trial design using Markov models with applications to autoimmune disease. / Eggleston, Barry S.; Ibrahim, Joseph G.; Catellier, Diane.

In: Contemporary Clinical Trials, Vol. 63, 01.12.2017, p. 73-83.

Research output: Contribution to journalArticle

@article{4c5b48b0b0bb4142a3c8283577981dfe,
title = "Bayesian clinical trial design using Markov models with applications to autoimmune disease",
abstract = "Immune Thrombocytopenia is an autoimmune disease associated with bleeding that is treated by increasing the platelet count to a level where the chance of uncontrollable bleeding is low. Failure occurs when platelet counts are not raised sufficiently (initial failure), or when high platelet counts are not maintained after initial success (relapse). In this paper, we propose a Bayesian clinical trial design that uses a Markov multistate model along with a power prior for the parameters which incorporates historical control data to estimate transition rates among two randomized groups as defined by the model. A detailed simulation is carried out to examine the operating characteristics of a trial to test whether a new treatment reduces the relapse rate by 40{\%} relative to standard care when data from 60 historical controls treated with standard care is available. We also use simulated data to demonstrate effects of discordance between historical and randomized controls on the estimated hazard ratios. Finally, we use a simulated trial to demonstrate briefly what type of results the model can give and how those results can be used to address hypotheses regarding treatment effects. Using simulated data, we show that the model yields good operating characteristics when the historical and randomized controls are from the same population, and demonstrate how discordance between the control groups affects the operating characteristics.",
keywords = "Bayesian methods, Clinical trial design, Illness-death model, Markov models",
author = "Eggleston, {Barry S.} and Ibrahim, {Joseph G.} and Diane Catellier",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.cct.2017.02.004",
language = "English (US)",
volume = "63",
pages = "73--83",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Bayesian clinical trial design using Markov models with applications to autoimmune disease

AU - Eggleston, Barry S.

AU - Ibrahim, Joseph G.

AU - Catellier, Diane

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Immune Thrombocytopenia is an autoimmune disease associated with bleeding that is treated by increasing the platelet count to a level where the chance of uncontrollable bleeding is low. Failure occurs when platelet counts are not raised sufficiently (initial failure), or when high platelet counts are not maintained after initial success (relapse). In this paper, we propose a Bayesian clinical trial design that uses a Markov multistate model along with a power prior for the parameters which incorporates historical control data to estimate transition rates among two randomized groups as defined by the model. A detailed simulation is carried out to examine the operating characteristics of a trial to test whether a new treatment reduces the relapse rate by 40% relative to standard care when data from 60 historical controls treated with standard care is available. We also use simulated data to demonstrate effects of discordance between historical and randomized controls on the estimated hazard ratios. Finally, we use a simulated trial to demonstrate briefly what type of results the model can give and how those results can be used to address hypotheses regarding treatment effects. Using simulated data, we show that the model yields good operating characteristics when the historical and randomized controls are from the same population, and demonstrate how discordance between the control groups affects the operating characteristics.

AB - Immune Thrombocytopenia is an autoimmune disease associated with bleeding that is treated by increasing the platelet count to a level where the chance of uncontrollable bleeding is low. Failure occurs when platelet counts are not raised sufficiently (initial failure), or when high platelet counts are not maintained after initial success (relapse). In this paper, we propose a Bayesian clinical trial design that uses a Markov multistate model along with a power prior for the parameters which incorporates historical control data to estimate transition rates among two randomized groups as defined by the model. A detailed simulation is carried out to examine the operating characteristics of a trial to test whether a new treatment reduces the relapse rate by 40% relative to standard care when data from 60 historical controls treated with standard care is available. We also use simulated data to demonstrate effects of discordance between historical and randomized controls on the estimated hazard ratios. Finally, we use a simulated trial to demonstrate briefly what type of results the model can give and how those results can be used to address hypotheses regarding treatment effects. Using simulated data, we show that the model yields good operating characteristics when the historical and randomized controls are from the same population, and demonstrate how discordance between the control groups affects the operating characteristics.

KW - Bayesian methods

KW - Clinical trial design

KW - Illness-death model

KW - Markov models

UR - http://www.scopus.com/inward/record.url?scp=85013754505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013754505&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2017.02.004

DO - 10.1016/j.cct.2017.02.004

M3 - Article

VL - 63

SP - 73

EP - 83

JO - Contemporary Clinical Trials

T2 - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -